Recent News

• 09.17.2025 - Rein Therapeutics Announces Publication of New Translational Data in iScience on Company’s Novel Therapy for Idiopathic Pulmonary Fibrosis
• 09.17.2025 - Rein Therapeutics Announces Publication of New Translational Data in iScience on Company’s Novel Therapy for Idiopathic Pulmonary Fibrosis
• 09.17.2025 - Rein Therapeutics Announces Publication of New Translational Data in iScience on Company’s Novel Therapy for Idiopathic Pulmonary Fibrosis
• 08.19.2025 - Rein Therapeutics Wins U.K. Approval to Launch Phase 2 Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
• 08.19.2025 - Rein Therapeutics Wins U.K. Approval to Launch Phase 2 Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
• 08.19.2025 - Rein Therapeutics Wins U.K. Approval to Launch Phase 2 Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
• 08.14.2025 - Rein Therapeutics to Present Novel IPF Science and Clinical Development Insights at IPF Summit 2025
• 08.14.2025 - Rein Therapeutics to Present Novel IPF Science and Clinical Development Insights at IPF Summit 2025
• 08.14.2025 - Rein Therapeutics to Present Novel IPF Science and Clinical Development Insights at IPF Summit 2025
• 07.30.2025 - Rein Therapeutics Enters into Agreements for up to $21 Million in Flexible Financing

Recent Filings

• 09.09.2025 - 8-K Current report
• 09.05.2025 - EFFECT Notice of Effectiveness
• 09.03.2025 - S-1 General form for registration of securities under the Securities Act of 1933
• 08.19.2025 - 8-K Current report
• 08.19.2025 - EX-99.1 EX-99.1
• 08.14.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 07.30.2025 - 8-K Current report
• 07.30.2025 - 424B5 Prospectus [Rule 424(b)(5)]